Journal
TISSUE ENGINEERING PART C-METHODS
Volume 16, Issue 3, Pages 459-467Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/ten.tec.2009.0112
Keywords
-
Categories
Funding
- NIH [R01 HL083880]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083880] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Current methods for measuring collagen content in engineered tissues are incompatible with monitoring of collagen production because they require destruction of the tissue. We have implemented a luciferase-based strategy to monitor collagen production noninvasively. Fibrin-based tissue constructs made using vascular smooth muscle cells stably transfected with a collagen I promoter/luciferase transgene developed with collagen content comparable to control cells, but could be imaged noninvasively to follow collagen transcription during tissue growth in vitro. We showed that these cells reported collagen I production at the transcriptional level in response to the growth factor transforming growth factor-beta 1 and fibrinolytic inhibition by e-aminocaproic acid and that these changes were consistent with changes at the mRNA and protein levels. As these cells report collagen changes instantly and without tissue destruction, they will facilitate construct optimization using multiple stimuli to produce functional engineered tissues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available